Literature DB >> 11384674

Double-blotting: a solution to the problem of non-specific binding of secondary antibodies in immunoblotting procedures.

F Lasne1.   

Abstract

"Double-blotting" (DB) was developed to overcome the problem of non-specific binding of secondary antibodies in immunoblotting (IB). After it had been probed by the primary antibody, the membrane with the blotted proteins was assembled with a second blank membrane and submitted to a second blotting under acidic conditions. The primary antibody molecules were thus desorbed from their corresponding antigen and transferred onto the second membrane, whereas the antigen and the interfering proteins remained bound to the first one. The second membrane could then be probed by the secondary antibodies without the risk of non-specific binding. This method was developed for the study of erythropoietin (EPO) in concentrated urine since a strong non-specific binding of biotinylated secondary antibodies to some urinary proteins had been observed using classical IB protocols.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11384674     DOI: 10.1016/s0022-1759(01)00355-6

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  10 in total

Review 1.  Pharmacokinetics/pharmacodynamics of recombinant human erythropoietins in doping control.

Authors:  Emmanuelle Varlet-Marie; Aurélie Gaudard; Michel Audran; Francoise Bressolle
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

Review 2.  Drugs for increasing oxygen and their potential use in doping: a review.

Authors:  Aurelie Gaudard; Emmanuelle Varlet-Marie; Francoise Bressolle; Michel Audran
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

3.  Detection of continuous erythropoietin receptor activator in blood and urine in anti-doping control.

Authors:  Françoise Lasne; Laurent Martin; Jean Antoine Martin; Jacques de Ceaurriz
Journal:  Haematologica       Date:  2009-06       Impact factor: 9.941

4.  Pharmacokinetic-pharmacodynamic modelling of recombinant human erythropoietin in athletes : a population approach.

Authors:  A Gaudard; E Varlet-Marie; M Audran; R Gomeni; F Bressolle
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

5.  Improvement of band segmentation in Epo images via column shift transformation with cost functions.

Authors:  S Stolc; I Bajla
Journal:  Med Biol Eng Comput       Date:  2006-04-05       Impact factor: 2.602

6.  Site-specific DNA-antibody conjugates for specific and sensitive immuno-PCR.

Authors:  Stephanie A Kazane; Devin Sok; Edward H Cho; Maria Loressa Uson; Peter Kuhn; Peter G Schultz; Vaughn V Smider
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-15       Impact factor: 11.205

7.  Current markers of the Athlete Blood Passport do not flag microdose EPO doping.

Authors:  Michael Ashenden; Clare E Gough; Andrew Garnham; Christopher J Gore; Ken Sharpe
Journal:  Eur J Appl Physiol       Date:  2011-02-20       Impact factor: 3.078

8.  Quantitative analysis of images in erythropoietin doping control.

Authors:  I Bajla; I Holländer; G Gmeiner; Ch Reichel
Journal:  Med Biol Eng Comput       Date:  2005-05       Impact factor: 2.602

9.  Caspase activation, sialidase release and changes in sialylation pattern of recombinant human erythropoietin produced by CHO cells in batch and fed-batch cultures.

Authors:  Kok Hwee Chuan; Sing Fee Lim; Laurent Martin; Chee Yong Yun; Sophia O H Loh; Francoise Lasne; Zhiwei Song
Journal:  Cytotechnology       Date:  2006-09-20       Impact factor: 2.058

10.  Optimizing detection of erythropoietin receptor agonists from dried blood spots for anti-doping application.

Authors:  Carmel E Heiland; Magnus Ericsson; Anton Pohanka; Lena Ekström; Alexandre Marchand
Journal:  Drug Test Anal       Date:  2022-03-30       Impact factor: 3.234

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.